Artelo Biosciences, Inc. (ARTL)
ARTL Stock Price Chart
Explore Artelo Biosciences, Inc. interactive price chart. Choose custom timeframes to analyze ARTL price movements and trends.
ARTL Company Profile
Discover essential business fundamentals and corporate details for Artelo Biosciences, Inc. (ARTL) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
21 Jun 2019
Employees
7.00
Website
https://www.artelobio.comCEO
Gregory D. Gorgas
Description
Artelo Biosciences, Inc. functions as a clinical-stage biopharmaceutical enterprise dedicated to discovering and advancing therapies that modulate the endocannabinoid system. The company's robust developmental portfolio encompasses several promising candidates: ART27.13, a synthetic G protein-coupled receptor agonist currently undergoing Phase 1b/2a clinical investigation for cancer-related anorexia; ART12.11, a synthetic cannabidiol cocrystal being explored for inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor with potential applications in prostate and breast cancer treatment, as well as PTSD. Further extending its research efforts, Artelo has established a collaborative partnership with Trinity College Dublin to probe ART27.13's efficacy in addressing cancer cachexia. Established in 2011, the entity initially operated under the name Reactive Medical, Inc. before rebranding as Artelo Biosciences, Inc. in April 2017. Its corporate headquarters are situated in Solana Beach, California.
ARTL Financial Timeline
Browse a chronological timeline of Artelo Biosciences, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 12 Aug 2026
EPS estimate is -$0.72.
Earnings released on 14 May 2026
EPS came in at -$4.00 falling short of the estimated -$0.78 by -412.82%.
Stock split effective on 10 Mar 2026
Shares were split 1 : 3 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 24 Feb 2026
EPS came in at -$6.66 falling short of the estimated -$4.71 by -41.40%.
Earnings released on 12 Nov 2025
EPS came in at -$3.97 falling short of the estimated -$0.82 by -384.15%.
Earnings released on 13 Aug 2025
EPS came in at -$5.61 falling short of the estimated -$4.19 by -33.89%.
Stock split effective on 13 Jun 2025
Shares were split 1 : 6 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 13 May 2025
EPS came in at -$4.32 falling short of the estimated -$0.80 by -440.14%.
Earnings released on 3 Mar 2025
EPS came in at -$7.02 falling short of the estimated -$2.62 by -167.94%.
Earnings released on 12 Nov 2024
EPS came in at -$2.10 surpassing the estimated -$4.76 by +55.84%.
Earnings released on 13 Aug 2024
EPS came in at -$4.50 surpassing the estimated -$4.76 by +5.46%.
Earnings released on 13 May 2024
EPS came in at -$4.68 surpassing the estimated -$5.88 by +20.41%.
Earnings released on 25 Mar 2024
EPS came in at -$5.94 falling short of the estimated -$3.34 by -77.84%.
Earnings released on 13 Nov 2023
EPS came in at -$4.98 falling short of the estimated -$3.88 by -28.35%.
Earnings released on 10 Aug 2023
EPS came in at -$0.56 surpassing the estimated -$0.81 by +30.86%.
Earnings released on 11 May 2023
EPS came in at -$0.76 surpassing the estimated -$0.93 by +18.28%.
Earnings released on 31 Mar 2023
EPS came in at -$1.18 falling short of the estimated -$0.73 by -61.64%.
Earnings released on 8 Nov 2022
EPS came in at -$0.82 surpassing the estimated -$0.91 by +9.89%.
Stock split effective on 10 Aug 2022
Shares were split 1 : 15 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 9 Aug 2022
EPS came in at -$0.90 falling short of the estimated -$0.85 by -5.88%.
Earnings released on 12 May 2022
EPS came in at -$0.75 surpassing the estimated -$1.27 by +40.94%.
Earnings released on 12 Jan 2022
EPS came in at -$7.19 falling short of the estimated -$0.83 by -771.52%.
Earnings released on 29 Nov 2021
EPS came in at -$6.30 falling short of the estimated -$1.35 by -366.67%.
ARTL Stock Performance
Access detailed ARTL performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
